» Articles » PMID: 34543670

Quantification and Cytotoxicity of Degradation Products (chloropropanols) in Sucralose Containing E-liquids with Propylene Glycol and Glycerol As Base

Overview
Specialties Pharmacology
Toxicology
Date 2021 Sep 20
PMID 34543670
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Electronic cigarettes (e-cigarettes) have gained increasing popularity in recent years, mostly because they are supposed to be less harmful than regular cigarettes. Therefore, it is highly imperative to investigate possible noxious effects to protect the consumers. E-liquids consist of propylene glycol, glycerol, aroma compounds and sweeteners. One of these sweeteners is a chlorinated version of sucrose, namely sucralose. The aim of this work was to investigate degradation products of sucralose in the presence of propylene glycol and glycerol at different temperatures of commercially available e-cigarettes. Chemical analysis and biological tests were simultaneously performed on e-liquid aerosol condensates. The results of the chemical analysis, which was executed by employing GC-MS/GC-FID, demonstrated high amounts of various chloropropanols. The most abundant one is extremely toxic, namely 3-chloropropane-1,2-diol, which can be detected at concentrations ranging up to 10,000 mg/kg. Furthermore, a cytotoxicity investigation of the condensates was performed on HUVEC/Tert2 cells in which metabolic activity was determined by means of resazurin assay. The cellular metabolic activity significantly decreased by treatment with e-liquid aerosol condensate. Due to the results of this study, we advise against the use of sucralose as sweetener in e-liquids.

Citing Articles

Assessment of human abuse potential of an unflavored, sucralose-sweetened electronic cigarette in combustible cigarette smokers.

Maloney S, Hoetger C, Bono R, Lester Scholtes R, Combs M, Karaoghlanian N Exp Clin Psychopharmacol. 2024; 32(5):588-603.

PMID: 38815111 PMC: 11870153. DOI: 10.1037/pha0000720.


Sugars and Sweeteners in Tobacco and Nicotine Products: Food and Drug Administration's Regulatory Implications.

Rezk-Hanna M, Talhout R, Jordt S Nicotine Tob Res. 2022; 25(4):838-840.

PMID: 36148496 PMC: 10032193. DOI: 10.1093/ntr/ntac222.